Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.35 |
| ▸ | CDC25B | P30305 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19666079 | 1.00 | MEN1 (0.46) | MEN1KMT2ALMNANAAAMAPT | |
| SCHEMBL2186406 | 0.79 | MEN1 (0.68) | MEN1KMT2ALMNANAAATSHR | |
| SCHEMBL29606950 | 0.79 | MEN1 (0.68) | MEN1KMT2ALMNANAAATSHR | |
| SCHEMBL334304 | 0.79 | MEN1 (0.68) | MEN1KMT2ALMNANAAATSHR | |
| SCHEMBL2186409 | 0.79 | MEN1 (0.68) | MEN1KMT2ALMNANAAATSHR | |
| SCHEMBL18236136 | 0.76 | LMNA (0.44) | MEN1KMT2ALMNANAAAMAPT | |
| SCHEMBL19683920 | 0.76 | SMN1; SMN2 (0.45) | MEN1KMT2ALMNACYP2C19CYP3A4 | |
| SCHEMBL19683919 | 0.76 | SMN1; SMN2 (0.45) | MEN1KMT2ALMNACYP2C19CYP3A4 | |
| SCHEMBL16464737 | 0.76 | LMNA (0.46) | MEN1KMT2ALMNANAAATSHR | |
| SCHEMBL1459289 | 0.74 | LMNA (0.49) | MEN1KMT2ALMNANAAACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11648315-B2 | Silvestrol antibody-drug conjugates and methods of use | GENENTECH, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-11648315-B2 | Silvestrol antibody-drug conjugates and methods of use | GENENTECH, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| CN-109476648-B | Sevelamer antibody-drug conjugates and methods of use | 豪夫迈·罗氏有限公司 | 2022-09-13 | — | — | CN | disclosed |
| EP-3464280-B1 | SILVESTROL ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2021-10-06 | — | — | EP | disclosed |
| US-20200222545-A1 | SILVESTROL ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2020-07-16 | — | — | US | disclosed |
| US-20200222545-A1 | SILVESTROL ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2020-07-16 | — | — | US | disclosed |
| US-10639378-B2 | Silvestrol antibody-drug conjugates and methods of use | GENENTECH, INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-10639378-B2 | Silvestrol antibody-drug conjugates and methods of use | GENENTECH, INC. (US) | 2020-05-05 | — | — | US | disclosed |
| EP-3464280-A1 | SILVESTROL ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017214024-A1 | SILVESTROL ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017214024-A1 | SILVESTROL ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| US-20170348422-A1 | SILVESTROL ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2017-12-07 | — | — | US | disclosed |
| US-20170348422-A1 | SILVESTROL ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348422-A1 | SILVESTROL ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | SHBG, EPCAM, ITGAV | MEN1 3118/4885KMT2A 503/4885LMNA 2820/4885 |
| US-20200222545-A1 | SILVESTROL ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | SHBG, EPCAM, ITGAV | MEN1 3118/4885KMT2A 503/4885LMNA 2820/4885 |
| US-11648315-B2 | Silvestrol antibody-drug conjugates and methods of use | SHBG, EPCAM, ITGAV | MEN1 3118/4885KMT2A 503/4885LMNA 2820/4885 |
| US-10639378-B2 | Silvestrol antibody-drug conjugates and methods of use | SHBG, EPCAM, ITGAV | MEN1 3118/4885KMT2A 503/4885LMNA 2820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.